Saara Bryk1, Anniina Färkkilä, Ralf Bützow, Arto Leminen, Markku Heikinheimo, Mikko Anttonen, Annika Riska, Leila Unkila-Kallio. 1. *Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, †Children's Hospital, University of Helsinki and Helsinki University Central Hospital, and ‡Department of Pathology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland; and §Department of Pediatrics, Washington University School of Medicine, St Louis Children's Hospital, St Louis, MO.
Abstract
OBJECTIVE: The objective of this study was to evaluate clinical prognostic factors and survival of patients with ovarian granulosa cell tumors (GCTs) in a long-term follow-up study. METHODS: A total of 240 adult-type GCTs diagnosed in Helsinki University Central Hospital from 1956 to 2012 were histologically reevaluated. Data were analyzed for several clinical factors in relation to major developments in imaging, surgery, and chemotherapy: the old era (1956-1983) and the new era (1984-2012). Prognostic factors for survival were evaluated in the univariate and multivariate analyses. RESULTS: The original diagnosis was confirmed in 187 (77.9%) patients. The International Federation of Gynecology and Obstetrics stage I disease was present in 89.2%; stage II, in 7.0%; stage III, in 3.8%; and stage IV, in 0% of cases. The mean age at diagnosis (52.9 years) and the mean tumor size (10.8 cm) did not change significantly over time. The most common presenting symptom was abnormal bleeding, but 14% were asymptomatic. The mean follow-up period was 15.7 years. Recurrence rate was similar in both eras. The GCT-specific 5-, 10-, and 20-year survival rates were 95.6%, 88.1%, and 79.8% in the old era as well as 97.2%, 94.8%, and 94.8% in the new era, respectively. In the univariate analyses, old era, patient age older than 60 years, tumor size greater than 10 cm, advanced stage, residual tumor, and use of hormonal adjuvant treatment were associated with GCT-related deaths. Prior use of oral contraceptives and history of infertility improved survival rates. In the multivariate analysis, stage was the only independent prognostic factor for GCT-specific survival. CONCLUSIONS: An accurate histological diagnosis of GCT is essential. Stage IV disease is an extreme rarity. However, tumor stage overcomes other possible clinical prognostic factors for GCT-specific survival. Fertility-sparing surgery, the use of oral contraceptives, or hormonal replacement therapy seems not to be risk factors for survival.
OBJECTIVE: The objective of this study was to evaluate clinical prognostic factors and survival of patients with ovarian granulosa cell tumors (GCTs) in a long-term follow-up study. METHODS: A total of 240 adult-type GCTs diagnosed in Helsinki University Central Hospital from 1956 to 2012 were histologically reevaluated. Data were analyzed for several clinical factors in relation to major developments in imaging, surgery, and chemotherapy: the old era (1956-1983) and the new era (1984-2012). Prognostic factors for survival were evaluated in the univariate and multivariate analyses. RESULTS: The original diagnosis was confirmed in 187 (77.9%) patients. The International Federation of Gynecology and Obstetrics stage I disease was present in 89.2%; stage II, in 7.0%; stage III, in 3.8%; and stage IV, in 0% of cases. The mean age at diagnosis (52.9 years) and the mean tumor size (10.8 cm) did not change significantly over time. The most common presenting symptom was abnormal bleeding, but 14% were asymptomatic. The mean follow-up period was 15.7 years. Recurrence rate was similar in both eras. The GCT-specific 5-, 10-, and 20-year survival rates were 95.6%, 88.1%, and 79.8% in the old era as well as 97.2%, 94.8%, and 94.8% in the new era, respectively. In the univariate analyses, old era, patient age older than 60 years, tumor size greater than 10 cm, advanced stage, residual tumor, and use of hormonal adjuvant treatment were associated with GCT-related deaths. Prior use of oral contraceptives and history of infertility improved survival rates. In the multivariate analysis, stage was the only independent prognostic factor for GCT-specific survival. CONCLUSIONS: An accurate histological diagnosis of GCT is essential. Stage IV disease is an extreme rarity. However, tumor stage overcomes other possible clinical prognostic factors for GCT-specific survival. Fertility-sparing surgery, the use of oral contraceptives, or hormonal replacement therapy seems not to be risk factors for survival.
Authors: Stine E Weis-Banke; Mads Lerdrup; Daniela Kleine-Kohlbrecher; Faizaan Mohammad; Simone Sidoli; Ole N Jensen; Toshihiko Yanase; Tomoko Nakamura; Akira Iwase; Anthe Stylianou; Nadeem R Abu-Rustum; Carol Aghajanian; Robert Soslow; Arnaud Da Cruz Paula; Richard P Koche; Britta Weigelt; Jesper Christensen; Kristian Helin; Paul A C Cloos Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: Bin Yang; Yan Yu; Jing Chen; Yan Zhang; Ye Yin; Nan Yu; Ge Chen; Shifei Zhu; Haiyan Huang; Yongqun Yuan; Jihui Ai; Xinyu Wang; Kezhen Li Journal: Front Med Date: 2017-12-07 Impact factor: 4.592
Authors: Melissa K McConechy; Anniina Färkkilä; Hugo M Horlings; Aline Talhouk; Leila Unkila-Kallio; Hannah S van Meurs; Winnie Yang; Nirit Rozenberg; Noora Andersson; Katharina Zaby; Saara Bryk; Ralf Bützow; Johannes B G Halfwerk; Gerrit K J Hooijer; Marc J van de Vijver; Marrije R Buist; Gemma G Kenter; Sara Y Brucker; Bernhard Krämer; Annette Staebler; Maaike C G Bleeker; Markku Heikinheimo; Stefan Kommoss; C Blake Gilks; Mikko Anttonen; David G Huntsman Journal: J Natl Cancer Inst Date: 2016-06-13 Impact factor: 13.506
Authors: Powel Crosley; Anniina Farkkila; Adrianne L Jenner; Chloé Burlot; Olivia Cardinal; Kyle G Potts; Kate Agopsowicz; Marjut Pihlajoki; Markku Heikinheimo; Morgan Craig; Yangxin Fu; Mary M Hitt Journal: Int J Mol Sci Date: 2021-04-29 Impact factor: 5.923